(Q37191094)

18 August 2017

1 reference

title

Chemotherapy for metastatic disease: review from JCOG trials (English)

1 reference

18 August 2017

1 reference

1

Narikazu Boku

1 reference

18 August 2017

Gastrointestinal Oncology Study Group of Japan Clinical Oncology Group

series ordinal

2

1 reference

18 August 2017

14 June 2008

1 reference

International Journal of Clinical Oncology

18 August 2017

1 reference

18 August 2017

13

1 reference

18 August 2017

3

1 reference

18 August 2017

196-200

1 reference

https://scigraph.springernature.com/pub.10.1007/s10147-008-0784-0

18 August 2017

0 references

cites work

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10147-008-0784-0

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-008-0784-0

A cooperative randomized study on tegafur plus mitomycin C versus combined tegafur and uracil plus mitomycin C in the treatment of advanced gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-008-0784-0

Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-008-0784-0

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

21 January 2018

1 reference

12 December 2020

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

1 reference

12 December 2020

FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer

1 reference

12 December 2020

Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).

1 reference

12 December 2020

A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer

1 reference

12 December 2020

Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer

1 reference

12 December 2020

Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: report from the Japan Clinical Oncology Group (JCOG).

1 reference

12 December 2020

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

1 reference

12 December 2020

Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the

1 reference

12 December 2020

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

1 reference

12 December 2020

Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Grou

1 reference

12 December 2020

Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer

1 reference

12 December 2020

Phase II study of a combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG0002).

1 reference

12 December 2020

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

1 reference

12 December 2020

Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group

1 reference

12 December 2020

A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin

1 reference

12 December 2020

Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients

1 reference

12 December 2020

Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research

1 reference

12 December 2020

Initial or delayed chemotherapy with best supportive care in advanced gastric cancer.

1 reference

12 December 2020

Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer

1 reference

12 December 2020

Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group

1 reference

12 December 2020

Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer

1 reference

12 December 2020

Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions

1 reference

12 December 2020

10.1007/S10147-008-0784-0

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18553227